Genmab — Oktober 2019

[Bulder]

Doublo: Jo, lungekræft. Sammen med atezolizumab, som er en PD-L1 blokker. Regn2810 er en PD-1 blokker, så i samme familie.

[Bulder]

HVIS vi får data fra checkmate142, så vil vi se hvad dara kan sammen med en PD-1 blokker (nivolumab).

[Bulder]

Solsen, en af de mab's der potentielt flokkes i RA er jo Ofa!

[Doublo]

Tak for svar Sukkeralf, men er det ikke en fordel for Genmab?

[Solsen]

Ja det er rigtigt bulder. Men ufatteligt, hvis JNJ ikke gør noget, hvis de mener der er noget at komme efter. Potentialet er enormt.

[Solsen]

Men de skal måske ikke have mere at betale 20% royalty af

[Bulder]

De kan jo bare købe butikken, så er de ude over det problem

[Sukkeralf]

Just a moment...

(www.firstwordpharma.com)

[Sukkeralf]

Ved hvad Novo roder med angående DuoBody?

[peter12]

Det har været oppe før https://medwatch.dk/secure/Medicinal___Biotek/article10899921.ece

[Sukkeralf]

Takker- mon det kun er dette område. De udvidede jo antallet af licenser sidste år

[peter12]

Det kunne vel i princippet også være diabetes, hvis de kan bremse det tidligt ? Mener jeg har set en artikel på et tidspunkt

[peter12]

Der står lidt her https://www.houstonchronicle.com/news/health/article/Testing-for-antibodies-early-can-delay-or-prevent-6717454.php

[Bulder]

BMS aflægger regnskab i dag, ser jeg. Kan hænde der kommer noget om diverse checkmate studier på CC.

[E_L]

comparables:

[E_L]

REVLIMID sales for the third quarter were $2,770 million, an increase of 13 percent year-over-year. U.S. sales were $1,902 million and international sales were $868 million, an increase of 14 percent and 11 percent year-over-year, respectively. REVLIMID sales growth was driven primarily by the adoption of triplet therapy for myeloma resulting in increases in treatment duration and market share.

[E_L]

POMALYST/IMNOVID sales for the third quarter were $664 million, an increase of 29 percent year-over-year. U.S. sales were $469 million and international sales were $195 million, an increase of 31 percent and 25 percent year-over-year, respectively. POMALYST/IMNOVID sales growth was driven primarily by the adoption of triplet therapy for myeloma resulting in increases in treatment duration and market share.

[Solsen]

They are happy about the partner Daratumumab

[E_L]

[E_L]

for those that did not bother to read @gentogen 's link below, it clearly states "The ongoing combination trials in Multiple Myeloma and Lymphoma as well as combination trials with isatuximab and atezolizumab in solid tumors continue."